Actinium Pharmaceuticals (NYSE:ATNM) Downgraded by StockNews.com to “Sell”

StockNews.com cut shares of Actinium Pharmaceuticals (NYSE:ATNM) from a hold rating to a sell rating in a research report sent to investors on Monday.

Other equities research analysts also recently issued research reports about the company. B. Riley downgraded Actinium Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their target price for the company from $16.00 to $2.00 in a research report on Wednesday, August 7th. HC Wainwright reduced their price objective on shares of Actinium Pharmaceuticals from $50.00 to $4.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. Finally, Maxim Group lowered their target price on shares of Actinium Pharmaceuticals from $30.00 to $5.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Actinium Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $11.40.

Actinium Pharmaceuticals Price Performance

Shares of NYSE ATNM opened at $1.94 on Monday. The firm has a market cap of $60.53 million, a P/E ratio of -1.28 and a beta of 0.14. The business’s 50 day moving average price is $1.80. Actinium Pharmaceuticals has a 1 year low of $1.33 and a 1 year high of $10.24.

Institutional Trading of Actinium Pharmaceuticals

A number of large investors have recently modified their holdings of the stock. Los Angeles Capital Management LLC purchased a new position in Actinium Pharmaceuticals in the third quarter valued at $322,000. Interchange Capital Partners LLC acquired a new position in shares of Actinium Pharmaceuticals in the 3rd quarter valued at $37,000. Creative Financial Designs Inc. ADV raised its stake in Actinium Pharmaceuticals by 183.0% during the 3rd quarter. Creative Financial Designs Inc. ADV now owns 63,785 shares of the company’s stock worth $120,000 after acquiring an additional 41,250 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new position in Actinium Pharmaceuticals in the second quarter valued at $92,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Actinium Pharmaceuticals during the second quarter worth about $356,000. Hedge funds and other institutional investors own 27.50% of the company’s stock.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).